ArticleTheScientificWorldJournal2026
Multitarget Neuropharmacological Actions of Drimycarpus racemosus Hook. f. GC-MS-Guided In Vivo and In Silico Evidence of Anxiolytic and Antidepressant Potential.
Article in TheScientificWorldJournal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and depression are significant neurological disorders with limited treatment efficacy and notable side effects associated with conventional synthetic drugs. This study investigated the anxiolytic and antidepressant potential of the methanolic leaf extract of Drimycarpus racemosus Hook. f. (MEDR) using both in vivo behavioral models and in silico molecular docking approaches. GC-MS analysis of MEDR identified 39 phytochemical constituents, including bioactive terpenoids, phenolic compounds, and fatty acid esters. In vivo experiments were conducted (n = 5 per group) on Swiss albino mice randomly divided into control, standard (diazepam 1 mg/kg), and treatment groups receiving MEDR (200 and 400 mg/kg) using the elevated plus maze (EPM), hole-board test (HBT), light-dark box (LDB), and forced swim test (FST). MEDR exhibited significant dose-dependent effects. At 400 mg/kg, MEDR significantly increased time spent in the open arms of the EPM by approximately 89% (140.0 ± 1.79 s vs. 74.2 ± 2.71 s in control, ∗p < 0.05) and number of open-arm entries (17.2 ± 1.43 vs. 10.4 ± 1.57) while markedly reducing immobility time in the FST by ~44% (102.2 ± 1.16 s vs. 182.6 ± 1.94 s in control, ∗p < 0.05). These effects were comparable to the standard drug diazepam (1 mg/kg). Molecular docking studies against the potassium channel (PDB ID: 4UUJ), GABAA receptor (PDB ID: 6X3X), and human serotonin transporter (hSERT, PDB ID: 5I6X) revealed that β-sitosterol acetate and 2-[4-cyclohexylbutanoylamino]-3-chloro-1,4-naphthoquinone exhibited higher binding affinities than diazepam across all three targets. The combined in vivo and in silico findings indicate that D. racemosus exerts multitarget neuropharmacological effects, primarily through modulation of GABAergic and serotonergic systems. These results highlight the phytochemical richness and therapeutic promise of MEDR as a potential source for developing safe, plant-based neurotherapeutics for anxiety and depression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.